Boston Scientific (BSX) Non-Current Debt (2009 - 2026)

Boston Scientific has disclosed Non-Current Debt across 18 years of filings, most recently posting $11.0 billion for Q1 2026.

• Non-Current Debt for Q1 2026 came in at $11.0 billion, up 4.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.0 billion (up 4.33% YoY), and the FY2025 annual result was $11.1 billion, up 24.19% from the prior year.
• Non-Current Debt came in at $11.0 billion for Q1 2026 at Boston Scientific, down from $11.1 billion in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $11.1 billion in Q4 2025 to a low of $8.4 billion in Q3 2023.
• The 5-year median for Non-Current Debt is $9.0 billion (2024), against an average of $9.5 billion.
• Across the five-year window, Non-Current Debt slipped 6.31% in 2023 and grew 24.19% in 2025, its largest moves.
• Boston Scientific's Non-Current Debt stood at $8.9 billion in 2022, then dropped by 3.86% to $8.6 billion in 2023, then grew by 4.63% to $9.0 billion in 2024, then gained by 24.19% to $11.1 billion in 2025, then slipped by 1.34% to $11.0 billion in 2026.
• The last three Non-Current Debt figures came in at $11.0 billion (Q1 2026), $11.1 billion (Q4 2025), and $11.1 billion (Q3 2025), per Business Quant data.